Mubadala and Resilience Partner to Develop and Advance Biopharma Manufacturing in the UAE
Resilience Announces Equity Investment from Mubadala
Mubadala toestablishfirst of its kind Biopharma Manufacturing Facility in the region based in the United Arab Emirates
Agreement to strengthen and expand the UAE’sgrowing life sciences ecosystem
Abu Dhabi,January 10,2023– Mubadala Investment Company PJSC (Mubadala), an Abu Dhabi sovereign investor,and National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, have signed adeal to further advance the UAE’slife sciences ecosystem through biopharma manufacturing.
Through a development agreement, Mubadala will establish the new manufacturing facility, in which Resilience will operate and manufacturebiopharmaceutical-related products out of the United Arab Emirates. Therange of therapeutics will beused to treat complex diseases such as cancer, infectious diseases, and inflammatory and autoimmune disorders.The Abu Dhabi based facility will bethe first Goods Manufacturing Practice(GMP) biopharma facility in the UAE as well as the first of its kind in the region to manufacture essential life sciencesproducts for advanced biologics.Over the past two years, Mubadala has invested in multiple rounds of equity financingin Resilience.
The two parties will play to their strengths to realize their shared goals of success. As a strategic investor focused on accelerating the economic diversification of the UAE through innovative investments, Mubadala will leverage the existing capabilities of its portfolio company; Strata Manufacturing (Strata), the advanced manufacturing champion that currently builds complex parts for the aerospace sector. Inaddition, Mubadala will also seek to strengthen the UAE’s life sciences ecosystem by leveraging UAE initiatives such as the HOPE Consortium, an Abu Dhabi-led partnership which operates one of the largest and most complete end-to-end pharma supply chains on the market today.
Mubadala is at the forefront of the UAE’s healthcare industry and is advancing the development of the country’s life sciences sector, to build national capabilities and increase national drug security by fostering innovation andpartnerships to further enhance bio pharma-manufacturing capabilities that would essentially benefit the entire region. The agreement with Resilience builds on Mubadala’s decade of world-class patient care and its breakthrough health and wellness solutions.The partnership with Resilience also follows the recent announcement of Mubadala Health and G42 Healthcare joining forces into a new, first-of-its-kind integrated healthcare technology company poised to revolutionize the regional healthcare landscape and deliver a new approach to personalized, patient-centric care.
The agreement was witnessed byMusabbeh Al-Kaabi, Chief Executive Officer of UAE Investments at Mubadala and signed by BadrAl-Olama Executive Director, UAE Clusters at Mubadala and Rahul Singhvi, ScD, Chief Executive Officer of Resilience.
Commenting on the agreement, Badr Al-Olama Executive Director, UAE Investment Platformat Mubadala, said: “We are actively investing in innovation and firmly believe that,by strengthening Abu Dhabi’s national life sciences ecosystem,we are building a future focused, sustainable and knowledge based economy for the UAE. Through this agreement, Mubadala and its group companies will unlock further opportunities for growth within the life sciences ecosystem, and alongside our key partners, will play an instrumental role in establishinga state-of-the-art biopharma campus that will secure the region’s supply chain from Abu Dhabi.”
“We are excited to expand the footprint of our Resilience manufacturing network outside of North America. This is a significant milestone, not just for our company but also for our nation,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “We look forward to working alongside America’s allies in the region to ensure that trusted, cutting-edge biopharmaceutical manufacturing capacity is available to support local, regionaland global economies.”
National Resilience is an established biotechnology company headquartered in California in the United States of Americathat is building a network of high-tech, end-to-end manufacturing solutions with the aim of ensuringthat the existing and future needs for complex medicines aremetquickly, safely and at scale. The U.S.-basedcompany will provide manufacturing, technology and operational expertise tothe Abu Dhabi facility, and integrate it as a node within its global network of facilities.
This partnership is in the line with the UAE’s industrial strategy, which identifies life sciences as a priority sector. Under the strategy, the UAE is inviting investors, industrialists, and companies to launch operations in the country and benefit from its tremendousgrowth.
In the wake of the global COVID-19 pandemic, the life sciencessector has become one of the fastest-growing sectors globally, and a priority investment area for private equity and venture capital. The global life science products market is estimated to account for around US$5bn in terms of value by the end of 2027. Recognizing thishigh growth rate as well as the rising biopharmaceutical supply shortage globally, countries are actively onshoringbiopharmaceutical manufacturing capabilities, and the UAE has been a powerhouse in this journey to develop world-class national healthcare capabilities across the life sciences supply chain from biopharma manufacturing, through this agreement, to advanced patient-care services.
About Mubadala Investment Company
Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi.
Mubadala’s $284 billion (AED 1045 billion) portfolio spans six continents with interests in multiple sectors and asset classes. We leverage our deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates.
For more information about Mubadala Investment Company, please visit: www.mubadala.com
Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions with the aim of ensuringthat the treatmentsof today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience aims to free partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions.
For more information, visit www.Resilience.com.